JKJong R. Kim

Jong R. Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jong R. Kim has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity

    by Li Wang, Timothy Z. Chang, Yuan He, Jong R. Kim, Shelly Wang, Teena Mohan, Zachary Berman, S. Mark Tompkins, Ralph A. Tripp, Richard W. Compans, et al.


  • A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model

    by Beth C. Holbrook, Jong R. Kim, Lance K. Blevins, Matthew J. Jorgensen, Nancy D. Kock, Ralph B. D’agostino, S. Tyler Aycock, Mallinath B. Hadimani, S. Bruce King, Griffith D. Parks, et al.

    Influenza virus infection of neonates poses a major health concern, often resulting in severe disease and hospitalization. At present, vaccines for this at-risk population are lacking. Thus, development of an effective vaccine is an urgent need. In this study, we have used an innovative nonhuman primate neonate challenge model to test the efficacy of a novel TLR 7/8 agonist R848-conjugated influenza virus vaccine. The use of the intact virus represents a step forward in conjugate vaccine design because it provides multiple antigenic targets allowing for elicitation of a broad immune response. Our results show that this vaccine induces high-level virus-specific Ab- and cell-mediated responses in neonates that result in increased virus clearance and reduced lung pathology postchallenge compared with the nonadjuvanted virus vaccine. Surprisingly, the addition of a second TLR agonist (flagellin) did not enhance vaccine protection, suggesting that combinations of TLR that provide increased efficacy must be determined empirically. These data support further exploration of this new conjugate influenza vaccine approach as a platform for use in the at-risk neonate population.


  • Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells

    by Jong R. Kim, Stephen O. Mathew, Porunelloor A. Mathew


  • Open Access

    Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates

    by Jong R. Kim, Beth C. Holbrook, Sarah L. Hayward, Lance K. Blevins, Matthew J. Jorgensen, Nancy D. Kock, Kristina De Paris, Ralph B. D'Agostino, S. Tyler Aycock, Steven B. Mizel, et al.

    Influenza virus can cause life-threatening infections in neonates and young infants. Although vaccination is a major countermeasure against influenza, current vaccines are not approved for use in infants less than 6 months of age, in part due to the weak immune response following vaccination. Thus, there is a strong need to develop new vaccines with improved efficacy for this vulnerable population. To address this issue, we established a neonatal African green monkey (AGM) nonhuman primate model that could be used to identify effective influenza vaccine approaches for use in young infants. We assessed the ability of flagellin, a toll like receptor 5 (TLR5) agonist, to serve as an effective adjuvant in this at risk population. Four to six day old AGM were primed and boosted with inactivated PR8 influenza virus (IPR8) adjuvanted with either wild type or mutant flagellin (m229), the latter of which is incapable of signaling through TLR5. Increased IgG responses were observed following boost, as well as at early times after challenge in infants vaccinated with flagellin adjuvanted IPR8. Inclusion of flagellin during vaccination also resulted in a significantly increased number of influenza-specific T cells following challenge compared to infants vaccinated with m229 adjuvant. Finally, infants vaccinated with IPR8+flagellin exhibited reduced pathology in the lungs following challenge compared to those that received IPR8+m229. This study provides the first evidence of flagellin mediated enhancement of vaccine responses in nonhuman primate neonates.


  • CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes

    by Jong R. Kim, Nathan C. Horton, Stephen O. Mathew, Porunelloor A. Mathew

    Objective and design CS1 (CRACC, CD319, SLAMF7) is a member of the Signaling Lymphocyte Activation Molecule family expressed on immune cells mediating host defense. CS1 is a self-ligand and has both activating and inhibitory functions in Natural Killer cells. However, the function of CS1 in human monocytes is currently unknown. The objective of this study was to evaluate the control of CS1 surface expression in activated monocytes and to assess the effect of CS1 triggering on proinflammatory cytokine production by monocytes. Material, methods and treatment Human monocytes were isolated from PBMC of healthy volunteers by magnetic depletion method or FACS sorting. The monocytes were cultured with or without LPS (1 μg/ml) in the presence or absence of various pharmacological inhibitors to inhibit NF-кB and PI3K signaling pathways. The cells were stimulated with anti-CS1 antibody or isotype control. Total RNA was extracted and RT-PCR was performed using specific primers for CS1 and EAT-2. Cell supernatants were collected and cytokine levels (TNF-α and IL-12p70) were determined by sandwich ELISA. Results Our study revealed that adherent or LPS-activated monocytes express CS1, and CS1 induction is via NF-кB and PI3K pathways. Importantly, cross-linking CS1 resulted in reduced production of proinflammatory cytokines TNF-α and IL-12p70 by LPS-activated monocytes. Conclusions Our study demonstrated that CS1 plays an inhibitory role in human monocytes to control proinflammatory immune responses.


  • Open Access

    Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus

    by J. R. Kim, S O Mathew, R. K. Patel, R. M. Pertusi, P A Mathew

    Summary: CS1 (CRACC, CD319) and 2B4 (CD244), members of the signalling lymphocyte activation molecule (SLAM) family receptors, regulate various immune functions. Genes encoding SLAM family receptors are located at 1q23, implicated in systemic lupus erythematosus (SLE). In this study, we have investigated the expression and alternative splicing of CS1 and 2B4 in immune cells from SLE patients. The surface expression of CS1 and 2B4 on total peripheral blood mononuclear cells (PBMCs), T, B, natural killer (NK) cells and monocytes in 45 patients with SLE and 30 healthy individuals was analysed by flow cytometry. CS1-positive B cell population was increased significantly in SLE patients. Because CS1 is a self-ligand and homophilic interaction of CS1 induces B cell proliferation and autocrine cytokine secretion, this could account for autoreactive B cell proliferation in SLE. The proportion of NK cells and monocytes expressing 2B4 on their surface was significantly lower in patients with SLE compared to healthy controls. Our study demonstrated altered expression of splice variants of CS1 and 2B4 that mediate differential signalling in PBMC from patients with SLE.


  • Open Access

    Functional role of human NK cell receptor 2B4 (CD244) isoforms

    by Stephen O. Mathew, Krithi K. Rao, Jong R. Kim, Nowland D. Bambard, Porunelloor A. Mathew

    2B4 (CD244), a member of the signaling lymphocyte‐activation molecule (SLAM/CD150), is expressed on all NK cells, a subpopulation of T cells, monocytes and basophils. Human NK cells express two isoforms of 2B4, h2B4‐A and h2B4‐B that differ in a small portion of the extracellular domain. In the present investigation, we have studied the functions of h2B4‐A and h2B4‐B. Our study demonstrated that these two isoforms differ in their binding affinity for CD48, which results in differential cytotoxic activity as well as intracellular calcium release by NK cells upon target cell recognition. Analysis of the predicted 3‐D structure of the two isoforms showed conformational differences that could account for their differences in binding affinity to CD48. h2B4‐A was able to mediate natural cytotoxicity against CD48‐expressing K562 target cells and induce intracellular calcium release, whereas h2B4‐B showed no effects. NK‐92MI, U937, THP‐1, KU812, primary monocytes, basophils and NK cells showed expression of both h2B4‐A and h2B4‐B whereas YT and IL‐2‐activated NK cells did not show any h2B4‐B expression. Stimulation of NK cells through 2B4 resulted in decreased mRNA levels of both h2B4‐A and h2B4‐B indicating that down‐regulation of 2B4 isoforms may be an important factor in controlling NK cell activation during immune responses.


  • Open Access

    Human CD57+ germinal center-T cells are the major helpers for GC-B cells and induce class switch recombination

    by Jong R Kim, Hyung W Lim, Seung G Kang, Peter Hillsamer, Chang H Kim

    Background: The function of CD57+ CD4+ T cells, constituting a major subset of germinal center T (GC-Th) cells in human lymphoid tissues, has been unclear. There have been contradictory reports regarding the B cell helping function of CD57+ GC-Th cells in production of immunoglobulin (Ig). Furthermore, the cytokine and co-stimulation requirement for their helper activity remains largely unknown. To clarify and gain more insight into their function in helping B cells, we systematically investigated the capacity of human tonsil CD57+ GC-Th cells in inducing B cell Ig synthesis. Results: We demonstrated that CD57+ GC-Th cells are highly efficient in helping B cell production of all four subsets of Ig (IgM, IgG, IgA and IgE) compared to other T-helper cells located in germinal centers or interfollicular areas. CD57+ GC-Th cells were particularly more efficient than other T cells in helping GC-B cells but not naïve B cells. CD57+ GC-Th cells induced the expression of activation-induced cytosine deaminase (AID) and class switch recombination in developing B cells. IgG1-3 and IgA1 were the major Ig isotypes induced by CD57+ GC-Th cells. CD40L, but not IL-4, IL-10 and IFN-γ, was critical in CD57+ GC-Th cell-driven B cell production of Ig. However, IL-10, when added exogenously, significantly enhanced the helper activity of CD57+ GC-Th cells, while TGF-β1 completely and IFN-γ partially suppressed the CD57+ GC-Th cell-driven Ig production. Conclusions: CD57+CD4+ T cells in the germinal centers of human lymphoid tissues are the major T helper cell subset for GC-B cells in Ig synthesis. Their helper activity is consistent with their capacity to induce AID and class switch recombination, and can be regulated by CD40L, IL-4, IL-10 and TGF-β.


  • Unique gene expression program of human germinal center T helper cells

    by Chang H. Kim, Hyung W. Lim, Jong R. Kim, Lusijah Rott, Peter Hillsamer, Eugene C. Butcher

    Gene expression profiling was used to compare the gene expression patterns of human germinal center (GC) T helper (Th) cells with other CD4+ T-cell subsets (naive, central, and effector memory T cells). GC-Th cells, specifically localized in germinal centers to help B cells, are distantly related to central and effector memory T cells in global gene expression profiles. GC-Th cells displayed substantial differences in mRNA for adhesion molecules, chemoattractant receptors, and cytokines compared with other populations. Distinct expression of transcriptional factors by GC-Th cells is consistent with the hypothesis that they may be different from other T cells in cell lineage. Interestingly, CXCL13, a critical chemokine for B-cell entry to lymphoid follicles, is one of the most highly up-regulated genes in GC-Th cells. GC-Th cells (but not other T cells) produce and secrete large amounts of functional CXCL13 upon T-cell receptor activation, a process that is dependent on costimulation, requires translation and transcription, and is dramatically enhanced by activation in the presence of GC-B cells. This study revealed for the first time the unique gene expression program of GC-Th cells.